Vaxcyte to establish fill-finish manufacturing in North Carolina

Vaxcyte (PCVX) announced a new agreement with Thermo Fisher Scientific (TMO) to bring additional fill-finish commercial manufacturing for Vaxcyte’s broad-spectrum pneumococcal conjugate vaccines to the United States. As a key element of Vaxcyte’s long-term U.S. commercial supply strategy, Thermo Fisher will provide custom commercial fill-finish capacity for the Company’s broad-spectrum PCVs at its Greenville, North Carolina facility. The initiative, including both manufacturing and related services, signifies a long-term U.S. commercial manufacturing commitment for Vaxcyte representing up to $1B.